From Bench to Bedside: Expanding the Scope of Thioredoxin Reductase Inhibitors as Promising Therapeutics for Tumors, Inflammatory Disorders, and Infectious Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 20 May 2024 | Viewed by 137
Special Issue Editors
Interests: biopharmaceutics; cellular target-inhibitor interaction; nanomedicine; drug targeting; drug delivery; nanoparticle carrier; biochemical pharmacology; pharmaceutical biotechnology; thioredoxin reductase; thioredoxin; GPX4; anti-tumor drugs
Special Issues, Collections and Topics in MDPI journals
Interests: drugs based on targeting the regulation of thiol redox system; novel biopharmaceutical technology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
For advanced pharmaceutical research, key cellular targets are selected for drug screening and development. In this Special Issue, thioredoxin reductase 1, the major cytosolic species of mammalian TXNRDs, and bacterial thioredoxin reductase are regarded as important cellular targets for the discovery of novel leads and druggable compounds in anti-tumor, anti-inflammation, and anti-infection research.
This Special Issue aims to select all in-depth studies that focus on expanding the understanding of current druggable structures, enhancing the synergic effects of combined medication, improving pharmacological function, and decreasing toxicological side-effects. These studies on druggable compounds or components include research on natural herb extracts, noble-metal complexes, or antioxidants for pharmaceutical application, and involving free radical research, redox biology, and tumor microenvironment regulation, are hereby very warmly welcome.
The investigation of small molecule inhibitors and druggable components is not limited to the aforementioned natural resources, clinical drugs, or known structures, but could also be extended to creative chemicals, dyes, pigments, probes, nutrients, and biological trace elements. The purpose of this Special Issue is to call for all pharmaceutical and biotechnological opinions/studies on novel molecules/structures targeting cellular thioredoxin reductase, intended for clinical application in the effective therapy of human cancer, inflammations, and infectious diseases.
Subtopics:
- Small molecule inhibitors: designing, screening or validation
- Prodrug/drug discovery from natural herbal resources
- Antioxidants, trace elements, heavy metal ions, and other antitumor agents
- Medical plant extracts and tumor microenvironment regulation
- TXNRD-targeted free radical research and redox regulation
- Roles of TXNRD for preventing infection and controlling inflammation
- Pharmaceutical applications of new compounds targeting TXNRD
Dr. Jianqiang Xu
Prof. Dr. Jun Lu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- thioredoxin reductase
- thioredoxin
- pharmaceutical effect
- small molecule inhibitors
- natural herb extracts
- antioxidants
- trace elements
- drug screening/validation
- inhibitory effect
- mechanism
- redox regulation
- oxidative stress
- tumor cell death
- inflammation
- infection
